Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Baxter
Colorcon
Express Scripts
Moodys

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IXABEPILONE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Ixabepilone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004927 BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed Memorial Sloan Kettering Cancer Center Phase 1 1999-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.
NCT00004927 BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed National Cancer Institute (NCI) Phase 1 1999-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.
NCT00004927 BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed Bristol-Myers Squibb Phase 1 1999-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.
NCT00005807 BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer Completed National Cancer Institute (NCI) Phase 1 2000-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic, recurrent, or locally advanced, ovarian cancer, breast cancer, or metastatic or unresectable solid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ixabepilone

Condition Name

Condition Name for Ixabepilone
Intervention Trials
Breast Cancer 23
Metastatic Breast Cancer 17
Unspecified Adult Solid Tumor, Protocol Specific 9
Stage IV Breast Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ixabepilone
Intervention Trials
Breast Neoplasms 46
Carcinoma 11
Adenocarcinoma 9
Prostatic Neoplasms 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ixabepilone

Trials by Country

Trials by Country for Ixabepilone
Location Trials
United States 599
Italy 24
Japan 18
United Kingdom 15
Argentina 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ixabepilone
Location Trials
California 30
New York 30
Maryland 29
Florida 28
Texas 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ixabepilone

Clinical Trial Phase

Clinical Trial Phase for Ixabepilone
Clinical Trial Phase Trials
Phase 3 7
Phase 2 64
Phase 1/Phase 2 12
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ixabepilone
Clinical Trial Phase Trials
Completed 69
Terminated 19
Active, not recruiting 12
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ixabepilone

Sponsor Name

Sponsor Name for Ixabepilone
Sponsor Trials
National Cancer Institute (NCI) 52
Bristol-Myers Squibb 28
R-Pharm 18
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ixabepilone
Sponsor Trials
Industry 67
Other 55
NIH 53
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Dow
Baxter
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.